[1]
G. Perletti, “Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis”, AIUA, vol. 87, no. 2, pp. 121-129, Jul. 2015.